The Hang Seng Index rose 3.55% over the past week to close at 29288.68 points.

The Hong Kong stock market welcomed a number of major IPOs. A total of 1 IPO was submitted in the past week, and 3 pharmaceutical IPOs passed the hearing. Three more IPOs are in prospecting, the first of which was genetically tested for cancer early screening in China$Novartis Health-B (06606.HK) $Subscriptions are in full swing. Currently, they have received a margin of HK$15.61 billion, or 73,752 times the subscription amount.

Among the new stocks listed this week,$Kuaishou-W (01024.HK) $Hong Kong stocks set off a new feast. Futu closed up 192.7% in dark trading, earning HK$22,160 per lot, topping Futu's dark trading volume list. On the first day of listing, Kuaishou continued its impressive trend. It closed up nearly 161%, and its market capitalization reached HK$1232.45 billion, ranking eighth among Hong Kong stocks.

In terms of US stocks, China's largest multi-business cloud communication service provider$Ronglian Cloud (RAAS.US) $and a global clinical-stage immunotherapy company$Tianyan Pharmaceutical (ADAG.US) $It is currently being actively subscribed. It is expected that the subscription will end next Monday (2/8) and be officially listed on February 9.

Only 1 IPO was submitted in the past week.

Guanglian ProjectIt is a Hong Kong foundation contractor. According to Frost & Sullivan's report, in terms of revenue, the company ranked the fourth largest subcontractor for foundation work in Hong Kong in 2019, accounting for about 1.7% of the groundwork industry market share. During the track record period, the foundation works undertaken by the company mainly included excavation and side support and other related projects, including pile cap works, underground drainage works and site leveling works.

There have been 3 IPOs reported in the past week, all of which belong to the pharmaceutical sector.

$Novartis Health-B (06606.HK) $It is a pioneer in the colorectal cancer screening market in China. The company was founded in 2015 and focuses on home early screening and genetic testing services for high-incidence cancers. Its product pipeline covers bowel cancer, cervical cancer, stomach cancer and other fields. The company's two colorectal cancer screening products (Chang Weiqing® and PopPtube®) have been approved and commercialized by the China Drug Administration. Among them,Chang Weiqing is the first and only molecular cancer screening test approved by the National Drug Administration in China. PooPootube is China's first and only self-test FIT screening product approved by the National Drug Administration.

Notably, Novartis Health has received continued attention from world-renowned venture capitalists, top biomedical funds, and long-term investment institutions. Its shareholders include Junlian Capital, SoftBank China Capital, Viming Group, Qiming Venture Capital, Rock Springs (an investor in Exact Sciences, a benchmark for early cancer screening in the US), Lilly Asia Fund, OrbiMed, etc.

Nuohui Health is currently in a prospectus. It is expected that the subscription will end on February 10. It is expected that 76.598 million shares will be issued at an issue price of HK$22.7-26.66 per share, or 500 shares per lot.

New drugs from ZhaoyanIt is a domestic contract research organization specializing in new pharmacology and toxicology research. It has now become the largest contract research organization for non-clinical drug safety evaluation in China. Based on revenue in 2019, the market share is 15.5%. The company's business includes three aspects: non-clinical research, clinical trials and related services, and experimental model business.$Showan Shinyaku (603127.SH) $It was listed on the Shanghai Stock Exchange in 2017.

During the track record period, the company's business and profitability both achieved large-scale strong growth. Total revenue increased from RMB 301 million in 2017 to 639 million yuan in 2019, with a compound annual growth rate of 45.7%. Net profit increased from 80 million yuan to 188 million yuan during the same period, with a compound annual growth rate of 53.2%.

Saisheng PharmaceuticalIt is a biopharmaceutical company with an integrated platform for product development and commercialization. It mainly focuses on some of the largest and rapidly developing treatment areas in China where there are significant unmet medical needs, such as tumors and severe infections. Telford Capital is the company's single largest shareholder. Up to now, Telford Capital holds about 35.14% of the company's total issued share capital.

During the track record period, the company's revenue mainly came from sales of its own product, Nitaxen. According to the prospectus, Nitaxen was the first brand of a new thymic drug in China. It was recognized by doctors and patients for its potential benefits in treating SARS and COVID-19, and has huge market potential.

In the past week, a total of 3 IPOs were in prospecting status, all of which have been fully subscribed.

$Novartis Health-B (06606.HK) $Subscriptions are in full swing. As of 17:00 on February 6, a total financing subscription amount of HK$15.61 billion was recorded, with a margin spread of 73,752 times. The offering will end next Wednesday (February 10), and will be officially listed and traded on the Hong Kong Stock Exchange on February 18.

A total of 3 IPOs were listed on the Main Board in the past week.

National-level short video live streaming platform$Kuaishou-W (01024.HK) $It set off a new feast for Hong Kong stocks. According to data from the Hong Kong Stock Exchange, Kuaishou was subscribed 1201.16 times during the public sale phase, receiving nearly 1,423 million valid applications, surpassing Medu TechnologyIt became the largest number of IPOs ever purchased.It is worth noting that the final number of people who subscribed to Kuaishou through Futu exceeded 206,000, and the subscription amount exceeded HK$42.6 billion.It ranked second in Futu's IPO subscription amount and number of subscribers.

In Futu's dark trading, Kuaishou once rose to 266.1% intraday.In the end, it closed up 192.7%, earning HK$22,160 per lot, with a total turnover of HK$733 million, topping Futu's dark market turnover list.On the first day of listing, Kuaishou continued its impressive trend, surging nearly 161% at the close.The market capitalization reached HK$1232.45 billion, ranking eighth among Hong Kong stocks.

Moreover$Xintong Medical-B (02160.HK) $The performance was also impressive. The dark market closed up 73.36%, earning HK$8,950 per lot. By Friday's close, it had risen 40.82% during the week.

The placement results were announced on Friday$Beckon Medical-B (02170.HK) $The dark market closed 22.26%, earning HK$3,045 per lot, and will officially land on the Hong Kong Stock Exchange next Monday (February 8).